Innovation Pharmaceuticals Inc (IPIX)

[LilyGDog]

Very nice find Here Today and thanks for bringing that too my attention.

The Phase 2 Brilacidin for COVID-19 clinical trial is a randomized, double-blind, placebo-controlled, international, multi-center study with planned enrollment of ~120 subjects with moderate-to-severe COVID-19. Two treatment arms are enrolling patients—active and placebo, with ~60 patients per arm. The study protocol provides for 3 days of study drug administration.

• Active Arm (Brilacidin): Standard of Care + daily Brilacidin IV infusion for 3 days
• Control Arm (Placebo): Standard of Care + daily Saline IV infusion for 3 days

After an interim review, by an independent Data Monitoring Committee (DMC), dosing may be extended to 5 days.

Notice that they are testing Brilacidin while in USE with the Standard of Care!!!! Huge development!!!!